panretinal photocoagulasi pada diabetic retinopathh

clinical therapeutics

T h e n e w e ngl a nd j o u r na l o f m e dic i n e

n engl j med 365;16 nejm.org october 20, 20111520

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies,

the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the authors clinical recommendations.

Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Neil M. Bressler, M.D., Roy W. Beck, M.D., Ph.D., and Frederick L. Ferris III, M.D.

From the Department of Ophthalmolo-gy, Johns Hopkins University School of Medicine, Baltimore (N.M.B.); the Jaeb Center for Health Research, Tampa, FL (R.W.B.); and the National Eye Institute, National Institutes of Health, Bethesda, MD (F.L.F.). Address reprint requests to Dr. Ferris at the Division of Epidemiology and Clinical Applications, National Eye In-stitute, 10 Center Dr., MSC 1204, Bethesda, MD 20892, or at [email protected].

N Engl J Med 2011;365:1520-6.Copyright 2011 Massachusetts Medical Society.

A 55-year-old man with a 20-year history of type 2 diabetes mellitus was referred to a retina specialist after noticing a few black floaters in his left eye for the preceding week. His glycated hemoglobin level was 8.2%. He had no history of laser treatment for proliferative diabetic retinopathy in either eye. Ophthalmoscopic examination of the right eye showed venous beading, intraretinal microvascular abnormalities, and no macular edema. Ophthalmoscopic examination of the left eye showed extensive neovascularization of the disk, consisting of new vessels extending beyond the optic disk in all directions (Fig. 1A). The retina specialist diagnosed severe nonproliferative diabetic retinopathy in the right eye and high-risk proliferative diabetic retinopathy in the left eye, with no macular edema in either eye. The specialist recommended prompt initiation of panretinal photocoagulation in the left eye.

The Clinic a l Problem

Diabetic retinopathy is a common complication of diabetes mellitus. An analysis of pooled data from several population-based studies estimated that approximately 40% of patients with diabetes who are over the age of 40 years have some retinopa-thy, including 8.2% who have vision-threatening retinopathy (usually diabetic mac-ular edema but less frequently proliferative retinopathy).1 An increased duration of diabetes and poor glucose control are major risk factors for retinopathy.2,3

Diabetic retinopathy is a leading cause of visual loss and new-onset blindness in the United States for patients between the ages of 20 and 74 years,4 with 12,000 to 24,000 new cases of diabetic retinopathyinduced blindness each year.5 Data from the Dia-betic Retinopathy Study (ClinicalTrials.gov number, NCT00000160) indicate that ap-proximately half of all eyes with proliferative diabetic retinopathy that are left untreated will have profound vision loss (i.e., visual acuity of

clinical ther apeutics

n engl j med 365;16 nejm.org october 20, 2011 1521

to the formation of neovascularization, which may lead to vitreous hemorrhage or traction damage to the retina.

Retinal ischemia leads to the production of a variety of growth factors, including vascular en-dothelial growth factor (VEGF).7 These growth factors stimulate the formation of abnormal capil-laries from the retinal vessels on the surface of the optic disk, a condition that is termed neovascular-ization of the disk (Fig. 1A), or on the surface of the retina but not near or overlying the disk, a condition that is termed neovascularization else-where (image not shown). Neovascularization of the disk and neovascularization elsewhere are the hallmarks of proliferative diabetic retinopathy. A patient with these features may have 20/20 vision and no warning symptoms of visual impairment. However, substantial vision loss can occur as these new vessels and the contractile fibrous tissue that eventually surrounds them grow and either bleed into the vitreous cavity or cause detachment of the retina between the level of the photoreceptors and the retinal pigment epithelium.

Scatter, or panretinal, photocoagulation is the mainstay of treatment for proliferative diabetic retinopathy. Typically, 1200 to 1600 laser burns (approximately 500 m in size) on the retina are evenly spaced or scattered throughout the retinal tissue away from the macula, focally destroying outer photoreceptors and retinal pigment epithe-lium (Fig. 1B and 1C). The treatment, in general, is not applied directly to neovascularization on the surface of the retina and is never applied directly over neovascularization of the disk. Rather, the treatment is thought to exert its effect by destroy-ing pigment epithelial cells and overlying retinal tissue. The pigmented cells absorb the laser light, and the resultant heat causes cellular destruction of the outer retina.

After panretinal photocoagulation, there is im-proved oxygen supply to areas of inner retina that

had become oxygen-deprived because of poor per-fusion of inner retinal vessels. This occurs both because the choriocapillaris (the blood-vessel sup-ply to the rods and cones and pigment epithelium) is now physically closer to the inner retina and

Figure 1. Treatment Effects of Panretinal Photocoagulation.

A fundus photograph taken before treatment with panret-inal photocoagulation shows neovascularization (arrows) extending beyond the optic disk in all directions (Panel A). A fundus photograph of the same eye taken 4 days after treatment shows nearly complete disappearance of the neovascularization (Panel B). A follow-up fundus photo-graph taken 3 weeks after treatment shows the absence of neovascularization and the presence of pigmentation and increasing visibility of the laser burns (Panel C).

A

B

C

The New England Journal of Medicine Downloaded from nejm.org on March 18, 2014. For personal use only. No other uses without permission.

Copyright 2011 Massachusetts Medical Society. All rights reserved.



because the highly metabolically active rods and cones are no longer present to absorb oxygen from the choriocapillaris in the area of the burns. As a result, there is a decreasing number of viable hy-poxic cells in the inner retina producing VEGF and other growth factors.7 Without continuous produc-tion of VEGF, the new vessels generally regress and may disappear altogether, although stabilization of the neovascularization with no further growth also may occur. Rarely, neovascularization progresses despite laser therapy and can lead to vitreous hem-orrhage or retinal detachment; in such cases, vitrec-tomy may be necessary to preserve or restore vision.

Clinic a l E v idence

Several randomized clinical trials have evaluated the efficacy of panretinal photocoagulation in pa-tients with proliferative diabetic retinopathy; these studies were summarized in a systematic review in 2007.8 The Diabetic Retinopathy Study enrolled 1758 patients with a visual acuity of 20/100 or bet-ter in each eye and with either proliferative diabetic retinopathy in at least one eye or severe nonprolif-erative diabetic retinopathy in both eyes. Each pa-tient was randomly assigned to undergo panreti-nal photocoagulation in one eye, with the other eye serving as the untreated control. Panretinal photo-coagulation reduced the risk of severe vision loss (defined as visual acuity of 20/800 or worse at two consecutive 4-month visits) caused by complica-tions of proliferative retinopathy from 14.0% to 6.2% during a 2-year period6 and from 33.0% to 13.9% during a 5-year period.9

The Early Treatment Diabetic Retinopathy Study (ETDRS; NCT00000151) enrolled 3711 patients with mild-to-severe nonproliferative or early pro-

liferative diabetic retinopathy in both eyes. Each patient was randomly assigned to undergo early photocoagulation in one eye; photocoagulation was deferred in the other eye until high-risk prolif-erative retinopathy was detected. At 5 years, rates of severe vision loss were 2.6% with early treatment and 3.7% with deferred treatment.4 For patients with severe nonproliferative diabetic retinopathy (typically, extensive dot and blot hemorrhages, definite areas of venous beading, or a moderate amount of intraretinal microvascular abnormali-ties) or with early proliferative diabetic retinopathy, panretinal photocoagulation and vitrectomy when necessary reduced the 5-year risk of severe vision loss from more than 50% if left untreated to ap-proximately 4% of eyes and 1% of patients.10

Clinic a l Use

The current standard technique for applying pan-retinal photocoagulation has been elucidated in the guidelines of the Diabetic Retinopathy Clinical Research Network.11 Treatment is usually initiated on the day of diagnosis in patients with high-risk proliferative diabetic retinopathy, a finding that is considered to be an urgent clinical condition, since the risk of vitreous hemorrhage and vision loss in the short term is high if the retinopathy is not treat-ed promptly (Table 1).

There are no other absolute requirements (other than obtaining consent) before initiating treatment after the diagnosis has been made on ophthalmos-copy. However, a detailed retinal drawing of the neovascularization or retinal fundus photographs can be helpful in determining the response to treat-ment at follow-up. In addition, there are several ele-ments of a comprehensive ophthalmologic exami-nation that may be relevant to specific patients. For example, it is important to document the vi-sual acuity before treatment so that any subjective changes in vision after treatment can be quantified. Since panretinal photocoagulation can affect pe-ripheral vision, recognition of any peripheral-field defects before treatment is important. Measure-ment of intraocular pressure before the initiation of treatment is useful; if the pressure is elevated, it is important to differentiate unrelated open-angle glaucoma from neovascularization in the trabec-ular meshwork (leading to so-called neovascular glaucoma). Such neovascular glaucoma frequently can be managed by panretinal photocoagulation.

If macular edema is present and the proliferative retinopathy is considered to be less than high risk,

Table 1. Risk Factors for High-Risk Proliferative Diabetic Retinopathy.*

Any retinal neovascularization

Neovascularization at the disk or within one disk diameter of the optic disk

Severe neovascularization of the disk (i.e., at least one quarter of the area of the optic disk) or severe neovascularization elsewhere (i.e., at least half the area of the optic disk)

Preretinal hemorrhage (blood between the surface of the retina and the pos-terior surface of the vitreous) or vitreous hemorrhage (blood within the vitreous cavity)

* High-risk proliferative diabetic retinopathy is defined as proliferative diabetic retinopathy with at least three of the four risk factors listed. Patients who have neovascularization that is not severe and not at the disk and who do not have preretinal or vitreous hemorrhage have only one risk factor. An additional risk factor is counted for each of the other features present.





panretinal photocoagulation often may be delayed (though only for a few weeks or months) until after macular edema has been treated, since the panreti-nal treatment could worsen the macular edema. The use of antithrombotic agents, including aspirin, is not a contraindication to proceeding with treat-ment. For patients who are acutely ill, laser therapy can be delayed until the patient is able to attend an outpatient appointment. If hemorrhage does devel-op, the presence of blood in the vitreous may in-terfere with the performance of panretinal photo-coagulation, since the light energy will be absorbed before reaching the retina and the view of the ret-ina may be compromised. In this situation, there remain the options of waiting for the hemorrhage to clear or eventually proceeding with vitrectomy.

Panretinal photocoagulation typically is per-formed as an outpatient procedure in the office setting. The pupil is dilated, followed by admin-istration of a topical anesthetic. A specialized contact lens, coupled onto the cornea with an ophthalmic gel, is used to view the retina with a slit-lamp laser delivery system and to focus the laser appropriately onto the retina (Fig. 2).

An anesthetic injection in the retrobulbar, per-ibulbar, or sub-Tenons space can be administered if the patient cannot tolerate the discomfort of the laser burns. However, such anesthesia risks perfo-ration of the eye, hemorrhage into the retrobulbar space, or anesthetizing the extraocular muscles, resulting in a loss of the patients ability to direct his or her gaze and thereby making it difficult to reach peripheral areas of the retina.

With a slit-lamp delivery system, a green or yel-low laser with settings that produce a 500-m spot size on the retina is typically used, with a laser exposure time of 0.07 to 0.1 seconds. Power is adjusted to produce a mildly white retinal burn. Approximately 1200 to 1600 burns are adminis-tered; the edges of the burns are distributed about 1 burn width apart (Fig. 1B and 1C). The distribu-tion of burns is planned to avoid the optic disk (to reduce the risk of thermal damage to the optic nerve) and the macula (to reduce the risk of im-pairing central vision). Laser burns are generally not placed within the temporal retinal vessel ar-cades, and the burns extend anteriorly at least to the equator of the retina (the midline between the anterior and posterior poles of the retina).

Treatment with the slit-lamp delivery system can be facilitated with an automated-pattern-delivery device that uses extremely short duration burns (0.02 to 0.03 seconds) with smaller spot sizes on the retina (approximately 250 to 300 m); the total number of burns is increased (typically 1800 to 2400 burns) in order to cover a similar area of retinal tissue.

Instead of a slit-lamp delivery system, some ophthalmologists prefer an indirect laser system, in which a laser is applied by means of a head-mounted ophthalmoscope and a lens that is held above the eye (Fig. 3). This technique creates a virtual (indirect) image of the retina between the lens and the ophthalmoscope. The advantages of the indirect laser system are that it does not require the placement of a contact lens on the cornea and

Figure 2. Slit-Lamp Delivery System.

In this procedure, a specialized contact lens, coupled onto the cornea with an ophthalmic gel, is used to view the retina during panretinal photocoagulation. The lens is needed to view the retina, assist with immobilization of the eye during treatment, and allow the ophthalmol-ogist to focus the laser appropriately onto the retina.

Figure 3. Indirect Laser Delivery System.

In this procedure, the ophthalmologist applies the laser using a head-mounted ophthalmoscope and an indirect lens measuring 20, 28, or 30 diopters held above the eye. This creates a virtual (indirect) image of the retina between the lens and the ophthalmoscope and avoids the placement of a contact lens on the cornea.





that it can more readily penetrate vitreous hem-orrhage. With this system, a spot size of 400 to 500 m is created with an indirect lens measur-ing 20, 28, or 30 diopters with an exposure of 0.05 to 0.1 seconds.

Treatment with panretinal photocoagulation is completed in one or more sittings, depending on the patients tolerance for the discomfort of the laser. The degree of discomfort ranges from mild discomfort to more severe discomfort that can be tolerated only with retrobulbar anesthesia. If more than one sitting is required, the course of therapy is usually completed within a month after the ini-tiation of treatment. If both eyes require treatment, they can be treated on the same day, but most patients prefer to have the second eye treated at a later date (usually within a week after treatment of the first eye).

After any session of panretinal photocoagula-tion, the patient should be aware that vision in the treated eye will be blurry for the next several hours because of the use of bright light and placement of the corneal contact lens during treatment. In gen-eral, the patient should not drive home immedi-ately after the treatment.

Once panretinal photocoagulation is complet-ed, patients are advised to contact the ophthal-mologist if they have pain that is not relieved by over-the-counter analgesics or if they note any substantial vision loss. If there are no problems after completion of the treatment, follow-up evalu-ation usually occurs within the first month and then 3 to 4 months after the completion of treat-ment in order to confirm that the neovasculariza-tion either regresses or stabilizes. If the neovas-cularization increases in size or if new areas of neovascularization develop, then additional pan-retinal photocoagulation is applied.

In 2011, the cost of panretinal photocoagula-tion was estimated to be approximately $1,080 on the basis of the average Medicare charges for this procedure in the mid-Atlantic region. One analysis calculated that the overall cost of screening and treatment for eye disease in patients with diabetes mellitus is approximately $3,190 per quality-adjust-ed life-year saved.12

A dv er se Effec t s

The most common complication of panretinal photocoagulation is the exacerbation of macular edema. In the ETDRS, in patients with such ede-

ma involving the center of the macula at baseline, an evaluation that was performed 4 months after baseline panretinal photocoagulation showed that 19% of the patients lost approximately two or more lines on a visual-acuity chart, including 11% who lost approximately three or more lines (unpub-lished data). Patients with diabetic macular edema involving the center of the macula appear to be more likely to have increased macular edema and loss of visual acuity in the short term after pan-retinal photocoagulation13 than patients without macular edema who receive such treatment.14

Because panretinal photocoagulation destroys viable retinal tissue, the procedure can cause vi-sual symptoms related to the loss of function of the burned retinal tissue. Such symptoms include peripheral visual-field defects, reduced night vi-sion, diminished color vision, and decreased con-trast sensitivity.15 Other possible adverse effects include choroidal effusions or choroidal detach-ment (



Guidelines

The American Academy of Ophthalmologys Pre-ferred Practice Pattern for Diabetic Retinopathy,43 which is based on the Diabetic Retinopathy Study and the ETDRS (level 1 evidence), recommends panretinal photocoagulation for patients with high-risk proliferative diabetic retinopathy or a condition that is approaching high risk. On the basis of additional analyses of visual outcomes from the ETDRS, the Preferred Practice Pattern also states that for patients with severe nonproliferative diabetic retinopathy or proliferative diabetic reti-nopathy that is not high risk, panretinal photo-coagulation should be considered before the de-velopment of high-risk proliferative retinopathy, especially in patients with type 2 diabetes. The Preferred Practice Pattern notes that in some pa-tients with severe vitreous or preretinal hemor-rhage, it may be impossible to perform panretinal photocoagulation. In other cases, neovasculariza-tion may persist despite extensive panretinal pho-tocoagulation. In each of these circumstances, vitreous surgery may be indicated to remove hem-orrhage and fibrous tissue. In such cases, panreti-nal photocoagulation may be performed at the time of surgery with a laser probe inserted into the middle cavity of the eye.

R ecommendations

The patient who is described in the vignette has proliferative diabetic retinopathy in the left eye with four high-risk features, including the presence of neovascularization, severe neovascularization, and neovascularization at the disk. A small amount of vitreous hemorrhage, not seen in the fundus pho-tograph, caused the apparent floaters and is the

fourth risk factor. Prompt initiation of panretinal photocoagulation in the left eye is recommended to reduce the risk of severe loss of visual acuity. Because the patient has no macular edema, it is unlikely that vision loss from macular edema that is caused by the treatment will develop. The consent process should include a discussion regarding the risks of permanent loss of peripheral and night vi-sion, as well as discomfort or pain during the pro-cedure and within 24 hours after the procedure. The patient should be advised that whether the treatment is completed in one or more sittings, it is important to complete panretinal photocoagu-lation as soon as possible before severe vitreous hemorrhage occurs. The patient will need to return for follow-up approximately a month after pan-retinal photocoagulation is completed. Also, the right eye needs to be monitored approximately ev-ery 4 months for progression to proliferative dia-betic retinopathy, because of the presence of severe nonproliferative diabetic retinopathy in that eye. Some ophthalmologists might initiate treatment in the right eye at this point, because with long-term follow-up, virtually all such eyes eventually need treatment.44 Finally, the patient should be remind-ed to work with his primary care provider to try to optimize both diabetes management and gen-eral medical care, because control of diabetes and blood pressure can influence the progression of retinopathy.45,46

Dr. Bressler reports that his institution has received grant support from Abbott Medical Optics, Alimera Sciences, Allergan, Bausch & Lomb, ForSight Labs, Genzyme, Lumenis, Notal Vision, Novartis, QLT, Regeneron, and Genentech. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank the Diabetic Retinopathy Clinical Research Network for providing background material on proliferative diabetic reti-nopathy and diabetic macular edema.

References

1. Kempen JH, OColmain BJ, Leske MC, et al. The prevalence of diabetic retinopa-thy among adults in the United States. Arch Ophthalmol 2004;122:552-63.2. Diabetes Control and Complications Research Group. The relationship of gly-cemic exposure (HbA1c) to the risk of de-velopment and progression of retinopathy in the Diabetes Control and Complica-tions Trial. Diabetes 1995;44:968-83.3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.

4. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagu-lation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991; 98:Suppl:766-85.5. National diabetes fact sheet, 2007: gen-eral information and national estimates on diabetes in the United States. (http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf.)6. The Diabetic Retinopathy Study Re-search Group. Preliminary report on ef-fects of photocoagulation therapy. Am J Ophthalmol 1976;81:383-96.

7. Aiello LP. Angiogenic pathways in di-abetic retinopathy. N Engl J Med 2005; 353:839-41.8. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007;298:902-16.9. The Diabetic Retinopathy Study Re-search Group. Indications for photoco-agulation treatment of diabetic retinopa-thy: diabetic retinopathy study report no. 14. Int Ophthalmol Clin 1994;27:239-53.10. Ferris FL III. How effective are treat-ments for diabetic retinopathy? JAMA 1993; 269:1290-1.





11. Diabetic Retinopathy Clinical Research Network. An observational study of the development of diabetic macular edema following scatter laser photocoagulation. (http://drcrnet.jaeb.org/Studies.aspx? RecID=142.)12. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic reti-nopathy. Ann Intern Med 1996;124:164-9.13. Diabetic Retinopathy Clinical Re-search Network. Randomized trial evalu-ating short-term effects of intravitreal ra-nibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiv-ing panretinal photocoagulation. Retina 2011;31:1009-27.14. Idem. Observational study of the de-velopment of diabetic macular edema fol-lowing panretinal (scatter) photocoagula-tion given in 1 or 4 sittings. Arch Ophthalmol 2009;127:132-40.15. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for prolifera-tive diabetic retinopathy: a literature re-view. Retina 2007;27:816-24.16. Blankenship GW. A clinical compari-son of central and peripheral argon laser panretinal photocoagulation for prolifer-ative diabetic retinopathy. Ophthalmology 1988;95:170-7.17. Mensher JH. Anterior chamber depth alteration after retinal photocoagulation. Arch Ophthalmol 1977;95:113-6.18. Liang JC, Huamonte FU. Reduction of immediate complications after panretinal photocoagulation. Retina 1984;4:166-70.19. Yuki T, Kimura Y, Nanbu S, Kishi S, Shimizu K. Ciliary body and choroidal de-tachment after laser photocoagulation for diabetic retinopathy: a high-frequency ul-trasound study. Ophthalmology 1997;104: 1259-64.20. Huamonte FU, Peyman GA, Goldberg MF, Locketz A. Immediate fundus compli-cations after retinal scatter photocoagula-tion. I. Clinical picture and pathogenesis. Ophthalmic Surg 1976;7:88-99.21. Blondeau P, Pavan PR, Phelps CD. Acute pressure elevation following pan-retinal photocoagulation. Arch Ophthal-mol 1981;99:1239-41.22. Zamir E, Anteby I, Merin S. Choroidal effusion causing transient myopia after panretinal photocoagulation. Arch Oph-thalmol 1996;114:1284-5.23. Lerner BC, Lakhanpal V, Schocket SS. Transient myopia and accommodative pa-resis following retinal cryotherapy and panretinal photocoagulation. Am J Oph-thalmol 1984;97:704-8.24. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth

factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-50.25. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71.26. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in oc-ular fluid of patients with diabetic retinop-athy and other retinal disorders. N Engl J Med 1994;331:1480-7.27. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothe-lial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995;92:10457-61.28. Amano S, Rohan R, Kuroki M, Tolen-tino M, Adamis AP. Requirement for vas-cular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22.29. Folkman J. Tumor angiogenesis: ther-apeutic implications. N Engl J Med 1971; 285:1182-6.30. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental cho-roidal neovascularization with intravitreal anti-vascular endothelial growth factor an-tibody fragment. Arch Ophthalmol 2002; 120:338-46.31. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothe-lial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.32. Malecaze F, Clamens S, Simorre-Pina-tel V, et al. Detection of vascular endothe-lial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopa-thy. Arch Ophthalmol 1994;112:1476-82.33. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 2001; 158:1161-72.34. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovasculariza-tion and neovascular glaucoma in a non-human primate. Arch Ophthalmol 1996; 114:964-70.35. Spaide RF, Fisher YL. Intravitreal be-vacizumab (Avastin) treatment of prolif-erative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26: 275-8.36. Oshima Y, Sakaguchi H, Gomi F,

Tano Y. Regression of iris neovasculariza-tion after intravitreal injection of bevaci-zumab in patients with proliferative dia-betic retinopathy. Am J Ophthalmol 2006; 142:155-8.37. Mason JO III, Nixon PA, White MF. In-travitreal injection of bevacizumab (Avas-tin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-8.38. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic reti-nopathy. Ophthalmology 2006;113(10): 1695.e1-1695.e15.39. Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single in-travitreal injection of bevacizumab (Avas-tin). Clin Experiment Ophthalmol 2006; 34:802-3.40. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in dia-betic individuals. Ophthalmology 2006; 113:23-8.41. Diabetic Retinopathy Clinical Re-search Network. Randomized trial evalu-ating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmol-ogy 2010;117:1064-77.42. Bressler NB, Edwards AR, Beck RW, et al. Exploratory analysis of diabetic reti-nopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Oph-thalmol 2009;127:1566-71.43. American Academy of Ophthalmology Retinal Panel. Preferred practice patterns. Diabetic retinopathy. San Francisco: Amer-ican Academy of Ophthalmology, 2009. (http://one.aao.org/CE/PracticeGuidelines/ SummaryBenchmark.aspx?cid= ea5c6d25-2ab9-4398-b00b-8efcb8cc5bc7.)44. Chew EY, Ferris FL III, Csaky KG, et al. The long-term effects of laser photoco-agulation treatment in patients with dia-betic retinopathy: the Early Treatment Diabetic Retinopathy follow-up study. Ophthalmology 2003;110:1683-9.45. The Diabetes Control and Complica-tions Trial Research Group. The effect of intensive treatment of diabetes on the de-velopment and progression of long-term complications in insulin-dependent diabe-tes mellitus. N Engl J Med 1993;329:977-86.46. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular compli-cations in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.Copyright 2011 Massachusetts Medical Society.



panretinal photocoagulasi pada diabetic retinopathh

Documents